Cargando…

In Vivo, In Vitro and In Silico Studies of the Hybrid Compound AA3266, an Opioid Agonist/NK1R Antagonist with Selective Cytotoxicity

AA3266 is a hybrid compound consisting of opioid receptor agonist and neurokinin-1 receptor (NK1R) antagonist pharmacophores. It was designed with the desire to have an analgesic molecule with improved properties and auxiliary anticancer activity. Previously, the compound was found to exhibit high a...

Descripción completa

Detalles Bibliográficos
Autores principales: Matalińska, Joanna, Lipiński, Piotr F. J., Kosson, Piotr, Kosińska, Katarzyna, Misicka, Aleksandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588979/
https://www.ncbi.nlm.nih.gov/pubmed/33086743
http://dx.doi.org/10.3390/ijms21207738
_version_ 1783600476144533504
author Matalińska, Joanna
Lipiński, Piotr F. J.
Kosson, Piotr
Kosińska, Katarzyna
Misicka, Aleksandra
author_facet Matalińska, Joanna
Lipiński, Piotr F. J.
Kosson, Piotr
Kosińska, Katarzyna
Misicka, Aleksandra
author_sort Matalińska, Joanna
collection PubMed
description AA3266 is a hybrid compound consisting of opioid receptor agonist and neurokinin-1 receptor (NK1R) antagonist pharmacophores. It was designed with the desire to have an analgesic molecule with improved properties and auxiliary anticancer activity. Previously, the compound was found to exhibit high affinity for μ- and δ-opioid receptors, while moderate binding to NK1R. In the presented contribution, we report on a deeper investigation of this hybrid. In vivo, we have established that AA3266 has potent antinociceptive activity in acute pain model, comparable to that of morphine. Desirably, with prolonged administration, our hybrid induces less tolerance than morphine does. AA3266, contrary to morphine, does not cause development of constipation, which is one of the main undesirable effects of opioid use. In vitro, we have confirmed relatively strong cytotoxic activity on a few selected cancer cell lines, similar to or greater than that of a reference NK1R antagonist, aprepitant. Importantly, our compound affects normal cells to smaller extent what makes our compound more selective against cancer cells. In silico methods, including molecular docking, molecular dynamics simulations and fragment molecular orbital calculations, have been used to investigate the interactions of AA3266 with MOR and NK1R. Insights from these will guide structural optimization of opioid/antitachykinin hybrid compounds.
format Online
Article
Text
id pubmed-7588979
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75889792020-10-29 In Vivo, In Vitro and In Silico Studies of the Hybrid Compound AA3266, an Opioid Agonist/NK1R Antagonist with Selective Cytotoxicity Matalińska, Joanna Lipiński, Piotr F. J. Kosson, Piotr Kosińska, Katarzyna Misicka, Aleksandra Int J Mol Sci Article AA3266 is a hybrid compound consisting of opioid receptor agonist and neurokinin-1 receptor (NK1R) antagonist pharmacophores. It was designed with the desire to have an analgesic molecule with improved properties and auxiliary anticancer activity. Previously, the compound was found to exhibit high affinity for μ- and δ-opioid receptors, while moderate binding to NK1R. In the presented contribution, we report on a deeper investigation of this hybrid. In vivo, we have established that AA3266 has potent antinociceptive activity in acute pain model, comparable to that of morphine. Desirably, with prolonged administration, our hybrid induces less tolerance than morphine does. AA3266, contrary to morphine, does not cause development of constipation, which is one of the main undesirable effects of opioid use. In vitro, we have confirmed relatively strong cytotoxic activity on a few selected cancer cell lines, similar to or greater than that of a reference NK1R antagonist, aprepitant. Importantly, our compound affects normal cells to smaller extent what makes our compound more selective against cancer cells. In silico methods, including molecular docking, molecular dynamics simulations and fragment molecular orbital calculations, have been used to investigate the interactions of AA3266 with MOR and NK1R. Insights from these will guide structural optimization of opioid/antitachykinin hybrid compounds. MDPI 2020-10-19 /pmc/articles/PMC7588979/ /pubmed/33086743 http://dx.doi.org/10.3390/ijms21207738 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Matalińska, Joanna
Lipiński, Piotr F. J.
Kosson, Piotr
Kosińska, Katarzyna
Misicka, Aleksandra
In Vivo, In Vitro and In Silico Studies of the Hybrid Compound AA3266, an Opioid Agonist/NK1R Antagonist with Selective Cytotoxicity
title In Vivo, In Vitro and In Silico Studies of the Hybrid Compound AA3266, an Opioid Agonist/NK1R Antagonist with Selective Cytotoxicity
title_full In Vivo, In Vitro and In Silico Studies of the Hybrid Compound AA3266, an Opioid Agonist/NK1R Antagonist with Selective Cytotoxicity
title_fullStr In Vivo, In Vitro and In Silico Studies of the Hybrid Compound AA3266, an Opioid Agonist/NK1R Antagonist with Selective Cytotoxicity
title_full_unstemmed In Vivo, In Vitro and In Silico Studies of the Hybrid Compound AA3266, an Opioid Agonist/NK1R Antagonist with Selective Cytotoxicity
title_short In Vivo, In Vitro and In Silico Studies of the Hybrid Compound AA3266, an Opioid Agonist/NK1R Antagonist with Selective Cytotoxicity
title_sort in vivo, in vitro and in silico studies of the hybrid compound aa3266, an opioid agonist/nk1r antagonist with selective cytotoxicity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588979/
https://www.ncbi.nlm.nih.gov/pubmed/33086743
http://dx.doi.org/10.3390/ijms21207738
work_keys_str_mv AT matalinskajoanna invivoinvitroandinsilicostudiesofthehybridcompoundaa3266anopioidagonistnk1rantagonistwithselectivecytotoxicity
AT lipinskipiotrfj invivoinvitroandinsilicostudiesofthehybridcompoundaa3266anopioidagonistnk1rantagonistwithselectivecytotoxicity
AT kossonpiotr invivoinvitroandinsilicostudiesofthehybridcompoundaa3266anopioidagonistnk1rantagonistwithselectivecytotoxicity
AT kosinskakatarzyna invivoinvitroandinsilicostudiesofthehybridcompoundaa3266anopioidagonistnk1rantagonistwithselectivecytotoxicity
AT misickaaleksandra invivoinvitroandinsilicostudiesofthehybridcompoundaa3266anopioidagonistnk1rantagonistwithselectivecytotoxicity